尿路上皮癌免疫治疗的研究进展

尿路上皮癌(UC)是泌尿系统常见的恶性肿瘤之一,其发病率及死亡率较高,几十年来,标准的治疗方案仍是基于顺铂的化学疗法,但是不良反应较大且疗效不佳.目前越来越多的免疫检查点抑制剂在治疗UC中显示出良好的疗效和安全性,在精密医学时代,UC的未来在于使用疗效更确切、不良反应更小、更有针对性的治疗.同样,开发可靠的预测生物标志...

Research progress in immunotherapy of urothelial carcinoma

Urothelial carcinoma(UC)is one of the most common malignant tumors in the urinary system.Its morbidity and mortality are high.For decades,the treatment plan of criteria is still based on cisplatin chemotherapy,but the side effects are relatively large.The effect is not good.At present,more and more immune checkpoint inhibitors have shown good efficacy and safety in the treatment of UC.In the era of precision medicine,the future of UC lies in the use of more accurate,less toxic,and more targeted treatments.Similarly,it is imperative to develop reliable predictive biomarkers and innovative treatment combinations.This article will review the research progress and future prospects of urothelial cancer immunotherapy in recent years.